Cited 17 times in
Healing effects of rebamipide and omeprazole in Helicobacter pylori-positive gastric ulcer patients after eradication therapy: a randomized double-blind, multinational, multi-institutional comparative study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이용찬 | - |
dc.date.accessioned | 2014-12-20T17:13:17Z | - |
dc.date.available | 2014-12-20T17:13:17Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0012-2823 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94186 | - |
dc.description.abstract | BACKGROUND AND AIMS: A recent placebo-controlled trial showed that rebamipide, which is a mucosal-protective antiulcer agent, promoted gastric ulcer healing without affecting the Helicobacter pylori status. We conducted a randomized, double-blind trial to compare the healing effects of rebamipide and the proton-pump inhibitor omeprazole in H. pylori-positive gastric ulcers after H. pylori eradication therapy. METHODS: After completion of 1 week of eradication therapy, 132 patients with H. pylori-positive gastric ulcer were enrolled in 5 Chinese and 4 Korean institutions. Patients were randomly assigned to take either 20 mg of omeprazole (n = 63) or 300 mg of rebamipide (n = 65) daily for 7 weeks. Healing was defined as complete recovery and S1 and S2 stage ulcer according to the Sakita-Miwa classification. RESULTS: Healing rates at 12 weeks were 81.5% (53/65) and 82.5% (52/63) in the rebamipide and omeprazole groups, respectively. There was no significant difference in treatment efficacy, as evidenced by gastric ulcer healing rates (absolute difference -1.0%; 95% confidence interval -10.7 to 8.7; p = 0.88). The H. pylori eradication rate and ulcer healing rate did not differ between the groups, the latter regardless of eradication outcome. CONCLUSIONS: Rebamipide is as effective as omeprazole in treating of H. pylori-positive gastric ulcer after eradication therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 221~229 | - |
dc.relation.isPartOf | DIGESTION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Alanine/adverseeffects | - |
dc.subject.MESH | Alanine/analogs & derivatives* | - |
dc.subject.MESH | Alanine/therapeutic use | - |
dc.subject.MESH | Amoxicillin/therapeutic use | - |
dc.subject.MESH | Anti-Bacterial Agents/therapeutic use | - |
dc.subject.MESH | Anti-UlcerAgents/therapeutic use* | - |
dc.subject.MESH | Clarithromycin/therapeutic use | - |
dc.subject.MESH | Double-BlindMethod | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | HelicobacterInfections/drugtherapy | - |
dc.subject.MESH | HelicobacterInfections/microbiology* | - |
dc.subject.MESH | Helicobacterpylori* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intention to Treat Analysis | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Omeprazole/adverseeffects | - |
dc.subject.MESH | Omeprazole/therapeutic use* | - |
dc.subject.MESH | Quinolones/adverseeffects | - |
dc.subject.MESH | Quinolones/therapeutic use* | - |
dc.subject.MESH | StomachUlcer/drugtherapy* | - |
dc.subject.MESH | StomachUlcer/microbiology | - |
dc.subject.MESH | StomachUlcer/pathology | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | WoundHealing | - |
dc.subject.MESH | Young Adult | - |
dc.title | Healing effects of rebamipide and omeprazole in Helicobacter pylori-positive gastric ulcer patients after eradication therapy: a randomized double-blind, multinational, multi-institutional comparative study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Song K.H. | - |
dc.contributor.googleauthor | Lee Y.C. | - |
dc.contributor.googleauthor | Fan D.-M. | - |
dc.contributor.googleauthor | Ge Z.-Z. | - |
dc.contributor.googleauthor | Ji F. | - |
dc.contributor.googleauthor | Chen M.-H. | - |
dc.contributor.googleauthor | Jung H.C. | - |
dc.contributor.googleauthor | Bo J. | - |
dc.contributor.googleauthor | Lee S.W. | - |
dc.contributor.googleauthor | Kim J.-H. | - |
dc.identifier.doi | 10.1159/000329353 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02988 | - |
dc.relation.journalcode | J00734 | - |
dc.identifier.eissn | 1421-9867 | - |
dc.identifier.pmid | 21757914 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/329353 | - |
dc.subject.keyword | Gastric ulcer | - |
dc.subject.keyword | Helicobacter pylori | - |
dc.subject.keyword | Omeprazole | - |
dc.subject.keyword | Proton pump inhibitor | - |
dc.subject.keyword | Rebamipide | - |
dc.subject.keyword | Treatment efficacy | - |
dc.contributor.alternativeName | Lee, Yong Chan | - |
dc.contributor.affiliatedAuthor | Lee, Yong Chan | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 84 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 221 | - |
dc.citation.endPage | 229 | - |
dc.identifier.bibliographicCitation | DIGESTION, Vol.84(3) : 221-229, 2011 | - |
dc.identifier.rimsid | 27297 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.